Pharming Group N.V.
PHAR
$7.65
-$0.675-8.11%
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | ||
|---|---|---|---|---|---|
| Net Income | -192.34% | 78.65% | -61.94% | -91.62% | |
| Total Depreciation and Amortization | -109.27% | -6.40% | 48.59% | 52.53% | |
| Total Amortization of Deferred Charges | -- | 22.78% | -- | -- | |
| Total Other Non-Cash Items | 84.15% | 2.97% | 306.59% | -24.93% | |
| Change in Net Operating Assets | -876.99% | -132.85% | -290.40% | 175.97% | |
| Cash from Operations | -37.42% | 121.15% | -72.04% | -340.65% | |
| Capital Expenditure | 72.24% | 0.33% | 57.02% | -47.98% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 155.24% | -3,734.04% | -132,100.00% | -1,058.31% | |
| Cash from Investing | 154.29% | -879.45% | -19,439.26% | -1,148.45% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -10,686.25% | -38.12% | -27.31% | -59.85% | |
| Issuance of Common Stock | -- | -78.13% | 944.74% | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 101.04% | -87.23% | -18.08% | -1,508.33% | |
| Cash from Financing | -976.61% | -466.91% | 372.92% | -482.93% | |
| Foreign Exchange rate Adjustments | 181.58% | -96.75% | 92.17% | 95.16% | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 94.04% | -61.97% | -3,894.69% | -27,601.72% | |
